Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.
Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.
复制标题
DOI：
10.1155/2018/3271948
复制
发表时间：
2018
影响因子：
2.8
通讯作者：
Martínez-Campa C
中科院分区：
文献类型：
--
作者：
Menéndez-Menéndez J;Martínez-Campa C
褪黑激素（N-乙酰基-5-甲氧基色胺）是一种由松果体主要在夜间合成和分泌的激素，因为光照会抑制其产生。最初，这种吲哚胺在恶性疾病中的作用被描述为内分泌反应性乳腺癌。来自多项临床试验和多项体内外实验研究的数据证明，松果体激素通过干扰雌激素信号介导的转录来抑制内分泌依赖性乳腺肿瘤，因此表现为选择性雌激素受体调节剂（SERM）。此外，褪黑激素通过控制参与雌二醇合成的酶来调节雌二醇的产生，充当选择性雌激素酶调节剂 (SEEM)。在过去的几年里，人们提出了更多的机制，包括膜褪黑激素受体 MT-1 和 MT-2 激活后触发的信号传导，或者针对钙调蛋白等分子的细胞内作用，或结合核内受体。在前列腺癌（参与雄激素合成的酶的调节以及雄激素受体水平和活性的调节）和卵巢癌中也获得了类似的结果。因此，肿瘤代谢、基因表达或表观遗传修饰受到调节，细胞生长受损，血管生成和转移受到抑制。在过去的十年中，更多的报告表明，褪黑激素是一种有前途的佐剂分子，当包含在旨在治疗内分泌反应性肿瘤的化疗或放疗方案中时，具有许多潜在的有益效果。因此，在这篇最先进的综述中，我们的目标是汇编有关吲哚胺在激素依赖性肿瘤中的抑癌作用的知识，以及有关褪黑激素与放射或化疗联合治疗乳腺癌、前列腺癌和卵巢癌时的作用的最新发现。由于褪黑激素没有毒性，因此很值得被视为有助于癌症预防和治疗的内源性药物。
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized and secreted by the pineal gland mainly during the night, since light exposure suppresses its production. Initially, an implication of this indoleamine in malignant disease was described in endocrine-responsive breast cancer. Data from several clinical trials and multiple experimental studies performed both in vivo and in vitro have documented that the pineal hormone inhibits endocrine-dependent mammary tumors by interfering with the estrogen signaling-mediated transcription, therefore behaving as a selective estrogen receptor modulator (SERM). Additionally, melatonin regulates the production of estradiol through the control of the enzymes involved in its synthesis, acting as a selective estrogen enzyme modulator (SEEM). Many more mechanisms have been proposed during the past few years, including signaling triggered after activation of the membrane melatonin receptors MT-1 and MT-2, or else intracellular actions targeting molecules such as calmodulin, or binding intranuclear receptors. Similar results have been obtained in prostate (regulation of enzymes involved in androgen synthesis and modulation of androgen receptor levels and activity) and ovary cancer. Thus, tumor metabolism, gene expression, or epigenetic modifications are modulated, cell growth is impaired and angiogenesis and metastasis are inhibited. In the last decade, many more reports have demonstrated that melatonin is a promising adjuvant molecule with many potential beneficial consequences when included in chemotherapy or radiotherapy protocols designed to treat endocrine-responsive tumors. Therefore, in this state-of-the-art review, we aim to compile the knowledge about the oncostatic actions of the indoleamine in hormone-dependent tumors, and the latest findings concerning melatonin actions when administered in combination with radio- or chemotherapy in breast, prostate, and ovary cancers. As melatonin has no toxicity, it may be well deserve to be considered as an endogenously generated agent helpful in cancer prevention and treatment.
登录
查看更多内容
影响因子：
10.3
作者：
Borin TF;Arbab AS;Gelaleti GB;Ferreira LC;Moschetta MG;Jardim-Perassi BV;Iskander AS;Varma NR;Shankar A;Coimbra VB;Fabri VA;de Oliveira JG;Zuccari DA
通讯作者：
Zuccari DA
影响因子：
10.3
作者：
Alonso-Gonzalez, Carolina;Gonzalez, Alicia;Cos, Samuel
通讯作者：
Cos, Samuel
影响因子：
10.3
作者：
BARTSCH, C;BARTSCH, H;GUPTA, D
通讯作者：
GUPTA, D
DOI：
10.1073/pnas.91.18.8517
发表时间：
1994-08-30
影响因子：
11.1
作者：
ARONICA, SM;KRAUS, WL;KATZENELLENBOGEN, BS
通讯作者：
KATZENELLENBOGEN, BS
影响因子：
10.3
作者：
Alvarez-Garcia, Virginia;Gonzalez, Alicia;Cos, Samuel
通讯作者：
Cos, Samuel